Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 58% Improvement Relative Risk Vitamin D  Basińska-Lewandowska et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 134 patients in Poland Fewer cases with higher vitamin D levels (p=0.016) c19early.org Basińska-Lewandowska et al., Nutrients, Mar 2023 Favors vitamin D Favors control

Frequency of COVID-19 Infection as a Function of Vitamin D Levels

Basińska-Lewandowska et al., Nutrients, doi:10.3390/nu15071581
Mar 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 134 patients in Poland between ages 6-50, showing higher risk of COVID-19 cases with vitamin D levels <12 ng/mL.
This is the 168th of 196 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 11,637 vigintillion).
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of case, 58.3% lower, RR 0.42, p = 0.02, high D levels (≥12ng/mL) 20 of 109 (18.3%), low D levels (<12ng/mL) 11 of 25 (44.0%), NNT 3.9.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Basińska-Lewandowska et al., 24 Mar 2023, retrospective, Poland, peer-reviewed, 5 authors. Contact: elzbieta.skowronska-jozwiak@umed.lodz.pl (corresponding author), mblbas@poczta.onet.pl, krzysztof.lewandowski@umed.lodz.pl, andrzej.lewinski@umed.lodz.pl, wojciech.horzelski@wmii.uni.lodz.pl.
This PaperVitamin DAll
AI generated summary. Current AI models can provide useful summaries for non-experts, but may be inaccurate and have limited ability to analyze larger context such as the entire evidence base for vitamin D.

People with very low vitamin D levels were more likely to develop COVID-19 than people with higher vitamin D levels.

This article is about the relationship between vitamin D levels and the risk of COVID-19 infection. The authors found that people with low vitamin D levels were more likely to develop COVID-19 than people with higher vitamin D levels. They found that this association was only significant for people with vitamin D levels <12 ng/mL.

The authors conclude that vitamin D may play a role in protecting against COVID-19.

This article is well-written and easy to follow. The authors provide a clear overview of the topic and support their findings with evidence from previous studies.

This article is relevant to the COVID-19 pandemic because it provides evidence that vitamin D deficiency may be a risk factor for COVID-19 infection. This information could be used to develop public health interventions to increase vitamin D levels in the population, which could potentially reduce the risk of COVID-19 infection.

There are a few limitations to this study. First, it was an observational study, which means that it cannot prove cause and effect. It is possible that other factors, such as health behaviors or socioeconomic status, could explain the association between vitamin D levels and the risk of COVID-19 infection. Second, the study was conducted in Poland, so the results may not be generalizable to other populations. Finally, the study did not measure vitamin D levels at the time of COVID-19 infection.

Here are some additional details about the study:

  • The study was conducted in Poland and included 134 healthy subjects.
  • The subjects' vitamin D levels were measured in March-April 2020.
  • Data on COVID-19 infection during the subsequent 12 months (prior to the vaccination program) were obtained from the national database of COVID-19 cases.
  • None of the subjects received any 25OHD supplements.
  • The average 25OHD concentrations were 18.1 ± 7.39 ng/mL (37.3% had 25OHD above 20 ng/mL).
  • Thirty-one (23.1%) patients developed COVID-19 infection, but an increased risk was only observed in individuals with 25OHD concentrations below 12 ng/mL (COVID-19 infection in 11 out of 25 patients (44%) with 25OHD < 12 ng/mL versus 20 out of 109 (18.3%) for those with 25OHD above 12 ng/mL, p = 0.0063).
  • A statistically significant relationship was not observed for subjects with 25OHD concentrations above 20 ng/mL (p = 0.2787).

Overall, this is a well-written and informative article that provides some evidence that vitamin D may play a role in protecting against COVID-19.

Frequency of COVID-19 Infection as a Function of Vitamin D Levels
Magdalena Basińska-Lewandowska, Krzysztof Lewandowski, Wojciech Horzelski, Andrzej Lewiński, Elżbieta Skowrońska-Jóźwiak
Nutrients, doi:10.3390/nu15071581
Background: It has been speculated that higher concentrations of 25-hydroxy-vitamin D (25OHD) provide some protection against COVID-19. We assessed whether there is any relationship between 25OHD concentrations and the subsequent development of COVID-19 infection. Materials and Methods: Concentrations of 25OHD were measured in March-April 2020 in 134 healthy subjects (57 males), age range 6-50, from a single urban general practice in central Poland. Data on COVID-19 infection during the subsequent 12 months (prior to the vaccination program) were obtained from the national database of COVID-19 cases. None of the subjects received any 25OHD supplements. Results: The average 25OHD concentrations were 18.1 ± 7.39 ng/mL (37.3% had 25OHD above 20 ng/mL). Thirty-one (23.1%) patients developed COVID-19 infection, but an increased risk was only observed in individuals with 25OHD concentrations below 12 ng/mL (COVID-19 infection in 11 out of 25 patients (44%) with 25OHD < 12 ng/mL versus 20 out of 109 (18.3%) for those with 25OHD above 12 ng/mL, p = 0.0063). Such a relationship was no longer observed for subjects with 25OHD concentrations above 20 ng/mL (p = 0.2787). Conclusions: Although only a minority of healthy subjects had 25OHD concentrations above 20 ng/mL in spring, an increased risk of subsequent COVID-19 infection was only observed in those with severe 25OHD deficiency (<12 ng/mL).
Conflicts of Interest: The authors declare no conflict of interest.
References
Baktash, Hosack, Patel, Shah, Kanbdiah et al., Vitamin D status and outcomes for hospitalised older patients with COVID-19, Postgrad Med. J, doi:10.1136/postgradmedj-2020-138712
Basi Ńska-Lewandowska, Lewi Ński, Horzelski, Skowro Ńska-Jóźwiak, Effect of Summer Sunshine Exposure on Vitamin D Status in Young and Middle Age Poles: Is 30 ng/mL Vitamin D Cut-Off Really Suitable for the Polish Population?, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph18158116
Binkley, Coursin, Krueger, Iglar, Heiner et al., Surgery alters parameters of vitamin D status and other laboratory results, Osteoporos Int, doi:10.1007/s00198-016-3819-9
Borsche, Glauner, Von Mendel, COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis, Nutrients, doi:10.3390/nu13103596
Cummings, Rosen, VITAL Findings-A Decisive Verdict on Vitamin D Supplementation, N. Engl. J. Med, doi:10.1056/NEJMe2205993
Grant, Lahore, Mcdonnell, Baggerly, French et al., Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths, Nutrients, doi:10.3390/nu12040988
Hernandez, Nan, Fernandez-Ayala, Garcia-Unzueta, Hernandez-Hernandez et al., Vitamin D Status in Hospitalized Patients with SARS-CoV-2
Holick, Binkley, Bischoff-Ferrari, Gordon, Hanley et al., Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline, J. Clin. Endocrinol. Metab, doi:10.1210/jc.2011-0385
Hosseini, El Abd, Ducharme, Effects of Vitamin D Supplementation on COVID-19 Related Outcomes: A Systematic Review and Meta-Analysis, Nutrients, doi:10.3390/nu14102134
Jolliffe, Holt, Greenig, Talaei, Perdek et al., Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: Phase 3 randomised controlled trial (CORONAVIT), BMJ, doi:10.1136/bmj-2022-071230
Leboff, Chou, Ratliff, Cook, Khurana et al., Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults, N. Engl. J. Med, doi:10.1056/NEJMoa2202106
Lopez-Castro, Coronavirus disease-19 pandemic and vitamin D: So much for so little?, Rev. Investig. Clin, doi:10.24875/RIC.21000305
Mercola, Grant, Wagner, Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity, Nutrients, doi:10.3390/nu12113361
Nogues, Ovejero, Pineda-Moncusi, Bouillon, Arenas et al., Calcifediol treatment and COVID-19-related outcomes, J. Clin. Endocrinol. Metab, doi:10.1210/clinem/dgab405
Oristrell, Oliva, Casado, Subirana, Domínguez et al., Vitamin D supplementation and COVID-19 risk: A population-based, cohort study, J. Endocrinol. Investig, doi:10.1007/s40618-021-01639-9
Oscanoa, Ghashut, Carvajal, Romero-Ortuno, Association between low serum vitamin D and increased mortality and severity due to COVID-19: Reverse causality?, Disaster Emerg. Med. J, doi:10.5603/DEMJ.a2022.0016
Perna, Is vitamin D supplementation useful for weight-loss programs? A systematic review and meta-analysis of randomized controlled trials, Medicina, doi:10.3390/medicina55070368
Perna, The enigma of vitamin D supplementation in aging with obesity, Minerva. Gastroenterol, doi:10.23736/S2724-5985.21.02955-7
Płudowski, Kos-Kudła, Walczak, Fal, Zozuli Ńska-Ziółkiewicz et al., Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland, Nutrients, doi:10.3390/nu15030695
Rosen, Abrams, Aloia, Brannon, Clinton et al., IOM committee members respond to Endocrine Society vitamin D guideline, J. Clin. Endocrinol. Metab, doi:10.1210/jc.2011-2218
Rubin, Sorting out whether vitamin D deficiency raises COVID-19 risk, JAMA, doi:10.1001/jama.2020.24127
Sassi, Tamone, D'amelio, Vitamin, Nutrient, Hormone, and Immunomodulator, Nutrients, doi:10.3390/nu10111656
Silva, Furlanetto, Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review, Nutr. Res, doi:10.1016/j.nutres.2014.12.008
Stroehlein, Wallqvist, Iannizzi, Mikolajewsja, Metzendorf et al., Supplementation for the treatment of COVID-19: A living systematic review, Cochrane Database Syst. Rev, doi:10.1002/14651858.CD015043
Sulli, Gotelli, Casabella, Paolino, Pizzorni et al., Vitamin D and Lung Outcomes in Elderly COVID-19 Patients, Nutrients, doi:10.3390/nu13030717
Wang, Joshi, Leopold, Jackson, Christensen et al., Association of vitamin D deficiency with COVID-19 infection severity: Systematic review and meta-analysis, Clin. Endocrinol, doi:10.1111/cen.14540
Zygmunt, Lewi Ński, Niedobór witaminy D a cię żki przebieg COVID-19 czy istnieje zwi ązek? [Vitamin D deficiency and severe course of COVID-19-Is there a connection?
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit